Eyevance Pharmaceuticals

Eyevance Pharmaceuticals

Ophthalmic solutions to improve vision and meet critical patient needs.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
*

$225m

Valuation: $225m

Acquisition
Total Funding000k
More about Eyevance Pharmaceuticals
Made with AI
Edit

Eyevance Pharmaceuticals specializes in developing innovative and impactful ophthalmic therapies focused on the ocular surface and anterior segment. The company aims to revolutionize eye care by providing affordable medications and cutting-edge technologies that address significant unmet needs. Eyevance serves a diverse range of clients, including healthcare providers and patients, primarily in the ophthalmology market. The business model revolves around the development, marketing, and sale of its proprietary eye care products. Revenue is generated through product sales and strategic partnerships, such as the recent acquisition by Santen Pharmaceuticals. Eyevance is committed to continuous learning, growth, and collaboration with customers to ensure the highest quality of care.

Keywords: ophthalmic therapies, ocular surface, anterior segment, eye care, innovative solutions, affordable medication, healthcare providers, product pipeline, strategic partnerships, Santen Pharmaceuticals.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo